Literature DB >> 24532044

Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.

Anne Lok1, Julie Mocquard, Jessie Bourcier, Laurence Redelsperger, Antoine Bonnet, Cecile Chauvin, Patrick Thomaré, Beatrice Mahé, Cyrille Touzeau, Philippe Moreau.   

Abstract

Entities:  

Keywords:  ASCT; VTD; multiple myeloma; subcutaneous bortezomib

Mesh：

Substances：

Year:  2014        PMID： 24532044      PMCID： PMC3943328          DOI： 10.3324/haematol.2013.100396

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P Moreau; J San Miguel; H Ludwig; H Schouten; M Mohty; M Dimopoulos; M Dreyling
Journal:  Ann Oncol       Date:  2013-08-16       Impact factor: 32.976

2.  Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.

Authors:  X Leleu; G Fouquet; B Hebraud; M Roussel; D Caillot; M L Chrétien; B Arnulf; R Szalat; L Garderet; L Benajiba; B Pegourie; C Regny; B Royer; A Caulier; A M Stoppa; S Garciaz; C Touzeau; C Chaleteix; J P Fermand; H A Loiseau; T Facon; M Attal; P Moreau
Journal:  Leukemia       Date:  2013-04-05       Impact factor: 11.528

Review 3.  Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.

Authors:  Philippe Moreau; Hervé Avet-Loiseau; Jean-Luc Harousseau; Michel Attal
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

5.  Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Authors:  Philippe Moreau; Herve Avet-Loiseau; Thierry Facon; Michel Attal; Mourad Tiab; Cyrille Hulin; Chantal Doyen; Laurent Garderet; Edouard Randriamalala; Carla Araujo; Gérard Lepeu; Gerald Marit; Denis Caillot; Martine Escoffre; Bruno Lioure; Lotfi Benboubker; Brigitte Pégourié; Brigitte Kolb; Anne Marie Stoppa; Jean-Gabriel Fuzibet; Olivier Decaux; Mamoun Dib; Christian Berthou; Carine Chaleteix; Catherine Sebban; Catherine Traullé; Jean Fontan; Marc Wetterwald; Pascal Lenain; Claire Mathiot; Jean-Luc Harousseau
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

6.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

7.  Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Authors:  Michele Cavo; Lucia Pantani; Maria Teresa Petrucci; Francesca Patriarca; Elena Zamagni; Daniela Donnarumma; Claudia Crippa; Mario Boccadoro; Giulia Perrone; Antonietta Falcone; Chiara Nozzoli; Renato Zambello; Luciano Masini; Anna Furlan; Annamaria Brioli; Daniele Derudas; Stelvio Ballanti; Maria Laura Dessanti; Valerio De Stefano; Angelo Michele Carella; Magda Marcatti; Andrea Nozza; Felicetto Ferrara; Vincenzo Callea; Catello Califano; Annalisa Pezzi; Anna Baraldi; Mariella Grasso; Pellegrino Musto; Antonio Palumbo
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 8.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

9.  Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.

Authors:  W Lamm; B Drach-Schauer; S Eder; J Drach
Journal:  Oncology       Date:  2013-09-27       Impact factor: 2.935

10.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Authors:  Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Dolores Hernández; Javier López-Jiménez; Javier de la Rubia; Miquel Granell; Joan Besalduch; Luis Palomera; Yolanda González; María Asunción Etxebeste; Joaquín Díaz-Mediavilla; Miguel T Hernández; Felipe de Arriba; Norma C Gutiérrez; María Luisa Martín-Ramos; María Teresa Cibeira; María Victoria Mateos; Joaquín Martínez; Adrián Alegre; Juan José Lahuerta; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113
  10 in total
  7 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Authors:  Maximilian Merz; Hans Salwender; Mathias Haenel; Elias K Mai; Uta Bertsch; Christina Kunz; Thomas Hielscher; Igor W Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Anna Jauch; Jens Hillengass; Marc S Raab; Baerbel Schurich; Markus Munder; Ingo G H Schmidt-Wolf; Christian Gerecke; Hans-Walter Lindemann; Matthias Zeis; Katja Weisel; Jan Duerig; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

3.  Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Grigoriy Rekhtman; Zvenyslava Masliak; Pawel Robak; Dixie-Lee Esseltine; Huaibao Feng; William Deraedt; Helgi van de Velde; Bertrand Arnulf
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

4.  Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.

Authors:  Annamaria Brioli; Beatrice Anna Zannetti; Elena Zamagni; Paola Tacchetti; Lucia Pantani; Katia Mancuso; Annalisa Pezzi; Serena Rocchi; Michele Cavo
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

5.  Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.

Authors:  Guangzhong Yang; Chuanying Geng; Yuan Jian; Huixing Zhou; Wenming Chen
Journal:  Adv Ther       Date:  2022-06-30       Impact factor: 4.070

Review 6.  Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Authors:  Barbara Muz; Rachel Nicole Ghazarian; Monica Ou; Micah John Luderer; Hubert Daniel Kusdono; Abdel Kareem Azab
Journal:  Drug Des Devel Ther       Date:  2016-01-11       Impact factor: 4.162

7.  In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line.

Authors:  Hatice Terzi; Ahmet Altun; Mehmet Şencan
Journal:  Indian J Med Res       Date:  2019-12       Impact factor: 2.375
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.